What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype.B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis.In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases.Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II.For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

Other Questions

Back to Help Center

What is included in the ImpriMed Immunoprofile service?

The ImpriMed Immunoprofile service includes both our Flow Cytometry and PARR reports. These comprehensive results can be used to detect the presence of lymphoma or leukemia and determine the disease subtype.

For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

How long until I get my ImpriMed report?

Our flow cytometry, PARR, and Immunoprofile reports are emailed to you 3-4 days after receipt of your patient’s sample(s) at our lab. The Personalized Prediction Profile reports are emailed to you 6-7 days after receipt of your patient’s sample(s) at our lab.

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/